Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.58 |
| ▸ | TLR9 | Q9NR96 | 13/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21645126 | 1.00 | TLR8 (0.58) | TLR8TLR9TLR7ACVR1NSD2 | |
| SCHEMBL21645129 | 1.00 | TLR8 (0.58) | TLR8TLR9TLR7ACVR1NSD2 | |
| SCHEMBL21645300 | 0.88 | TLR8 (0.42) | TLR8TLR9TLR7ELANE | |
| SCHEMBL21645301 | 0.88 | TLR8 (0.42) | TLR8TLR9TLR7ELANE | |
| SCHEMBL21645302 | 0.88 | TLR8 (0.42) | TLR8TLR9TLR7ELANE | |
| SCHEMBL23855097 | 0.86 | TLR8 (0.42) | TLR8TLR9TLR7ELANE | |
| SCHEMBL21661231 | 0.86 | TLR8 (0.42) | TLR8TLR9TLR7ELANE | |
| SCHEMBL21661233 | 0.86 | TLR8 (0.42) | TLR8TLR9TLR7ELANE | |
| SCHEMBL19828894 | 0.85 | TLR8 (0.51) | TLR8TLR9TLR7ACVR1NSD2 | |
| SCHEMBL16634353 | 0.85 | TLR8 (0.51) | TLR8TLR9TLR7ACVR1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| EP-3830080-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020025517-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | TLR8 2/4885TLR9 3/4885TLR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.